The 'Overweight' rating maintained by Morgan Stanley indicates that the firm believes Eli Lilly's stock will outperform the market in the future. The increase in the price target from $507 to $551 suggests that the firm sees significant upside potential for the stock. This is likely to have a positive impact on the stock's price in the short term.